Which critical medicines are in short supply in the European Union?
Here are the critical medicines in short supply in the EU, according to the latest available information from the EMA and ...
MedPage Today9d
Approved Sickle Cell Drug Fails to Beat Placebo in Trial
SUSTAIN was the basis for FDA approval and European Medicines Agency (EMA) approval for crizanlizumab for the prevention of vaso-occlusive crises in patients ages 16 years and older with sickle ...
US FDA expands approval for Alnylam's drug to treat rare heart disease
U.S. Food and Drug Administration approved Alnylam's drug to treat a rare and deadly heart disease on Thursday, allowing the ...
pharmaphorum1d
EMA’s strategy for speeding up drug approvals in the EU
The EMA is implementing major changes to accelerate drug approvals in the EU, addressing delays that affect patients and businesses alike. Following a turbulent period marked by Brexit and the ...
Posts falsely claim Pfizer published list of Covid-19 vaccine side effects
Pfizer's Covid-19 vaccine is considered by healthcare authorities to be safe and effective, with data gathered from billions ...
MIT Technology Review8d
This annual shot might protect against HIV infections
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
Zacks Investment Research on MSN1d
FDA Approves Novartis Drug for Rare Kidney Disease Treatment
Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved ...
Pharmabiz25d
EMA validates Gilead’s MAA and EU-Medicines for all application for twice-yearly lenacapavir for HIV prevention
Gilead Sciences, Inc. announced that the European Medicines Agency (EMA) has validated ... FDA’s acceptance of our New Drug Applications for lenacapavir for PrEP underscores the great interest in how ...
AOL11d
Compound versions of some weight loss drugs to be restricted
They are made by licensed pharmacies, but not approved or inspected by the FDA. Drug compounding is allowed when drugs are on the FDA's shortage list, or in circumstances when a patient can't take ...
Le Lézard2d
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis today announced that oral Fabhalta® (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with C3 glomerulopathy (C3G), to reduce proteinuria, ...
The Hill29d
Ozempic and Wegovy officially moved off FDA’s drug shortage list
The FDA’s drug shortage list now states that as of Feb. 21 ... “We are pleased the FDA has declared that supply of the only real, FDA-approved semaglutide medicines is resolved, affirming ...